Abstract Details

Title Understanding Factors Influencing Deterioration in Upper and Lower Extremity Outcomes in Multiple Sclerosis

Topic Multiple Sclerosis

Presentation(s) P1 - Poster Session 1 (11:45 AM-12:45 PM)

Poster/Presentation
Number 1-004

Objective In the realm of multiple sclerosis (MS) management, understanding the factors contributing to
significant deteriorations in mobility and dexterity is paramount. This retrospective study delves into
the intricate web of variables influencing ≥20% worsening in Timed 25-Foot Walk (T25FW) and 9-
Hole Peg Test (9HPT) outcomes over approximately one year in MS patients.

Background Our investigation involved a meticulous cross-sectional analysis of MS patients who underwent
T25FW and 9HPT tests approximately one year apart.

Design/Methods Patients were stratified into two distinct groups: those who encountered ≥20% worsening and a control
cohort devoid of such deterioration. Various parameters including demographic details, initial
Expanded Disability Status Scale (EDSS), disease type, lesion characteristics, and treatment history
were meticulously scrutinized. Binary logistic regression was then wielded to decipher the pivotal
factors impacting the decline in T25FW and 9HPT outcomes.

Results For the 9HPT cohort, comprising 47 individuals, 12 endured ≥20% worsening while 35 remained
stable. Intriguingly, no discernible factors emerged to elucidate the deterioration in 9HPT outcomes.
Conversely, in the T25FW cohort encompassing 91 patients, 41 manifested ≥20% worsening while 50
maintained stability. Remarkably, the presence of T1 black holes emerged as a significant contributor
to T25FW worsening (β=4.067, p=0.036), underscoring its prognostic relevance.

Conclusions This study offers profound insights into the determinants underpinning ≥20% deterioration in T25FW
and 9HPT outcomes among MS patients. Notably, the presence of T1 black holes surfaced as a pivotal
factor in precipitating T25FW deterioration, highlighting its clinical significance. These findings hold
promise in refining prognostic models and tailoring therapeutic interventions, thereby fostering a more
personalized approach to MS management.

Authors/Disclosures
Said Alizada, MD PRESENTER	Dr. Alizada has nothing to disclose.
Asiye Tuba Ozdogar, PhD	Miss Ozdogar has nothing to disclose.
Gozde D. Unal, Jr., PT	Miss Unal has nothing to disclose.
irem Kara, PhD	Miss Kara has nothing to disclose.
Nurbanu AYGUNDUZ YAPICI, MD	Dr. AYGUNDUZ YAPICI has nothing to disclose.
Serkan Ozakbas, MD (Department of Neurology Izmir University of Economics Medical Point Hospital)	Dr. Ozakbas has nothing to disclose.

��ɫ��

��ɫ��